Innitius
INNITIUS is a medical device startup based in Spain specializing in actionable diagnostics for women's health, particularly in differentiating false and true preterm labor threats. Their flagship product, FineBirth, is a portable diagnostic device combining novel Torsional Waves technology with Artificial Intelligence to assess cervical tissue consistency and provide real-time risk assessment of spontaneous preterm delivery within 7 days. The company aims to reduce unnecessary hospitalizations and healthcare costs associated with false preterm labor diagnoses. INNITIUS is in the clinical stage with ongoing trials and aims to become a leader in medical diagnostics by improving maternal and neonatal outcomes and building the largest cervical consistency database in Europe.
Innitius
INNITIUS is a medical device startup based in Spain specializing in actionable diagnostics for women's health, particularly in differentiating false and true preterm labor threats. Their flagship product, FineBirth, is a portable diagnostic device combining novel Torsional Waves technology with Artificial Intelligence to assess cervical tissue consistency and provide real-time risk assessment of spontaneous preterm delivery within 7 days. The company aims to reduce unnecessary hospitalizations and healthcare costs associated with false preterm labor diagnoses. INNITIUS is in the clinical stage with ongoing trials and aims to become a leader in medical diagnostics by improving maternal and neonatal outcomes and building the largest cervical consistency database in Europe.
TL;DR
Sector: Medical devices — obstetric diagnostics
Flagship product: FineBirth (torsional-wave cervical consistency diagnostic + AI)
Clinical stage: Clinical trials ongoing
Headquarters: Derio, País Vasco, Spain
Employees: 27
Company Overview
Problem Domain
Preterm birth risk assessment and prediction of induction labor success through noninvasive cervical diagnostics.
Industry
Medical devices
Funding Track Record
3800000.00
Reported grant
2342836.00
Reported funding from EIC
1800000.00
Reported seed round
450000.00
Reported convertible note
Investor Signal
“Supported by European innovation/grant organizations (European Innovation Council, EIT Health, ENISA) and regional recovery/fund programs”